An interventional study of HPV Self-Collection and Informational Intervention in Cervical Carcinoma, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Screening
This clinical trial studies whether a community based intervention improves cervical cancer screening (CCS) among women in the Hispanic and East African immigrant community. Previous research has shown that CCS remains low among women of the Hispanic and East African immigrant community due to lack of awareness about cervical cancer as well as recommended screening guidelines. The community based intervention in this trial will offer CCS in the Hispanic and East African immigrant community using a test that can be completed by the individual. The test uses a brush that is placed inside the vagina to collect a sample. The self-collected sample is then tested for a virus called human papillomavirus (HPV). Because some types of HPV can cause cervical cancer, checking for HPV, may lower a woman's chance of getting cervical cancer. A community based intervention may be an effective way to improve CCS among women in the Hispanic and East African immigrant community.
1,927 studies on the registry are indexed under Uterine Cervical Neoplasms; 576 are open to participants now.
This study's planned enrollment of 118 is above the median of 100 across 1,411 interventional studies indexed under Uterine Cervical Neoplasms.
Browse Uterine Cervical Neoplasms studies →Mayo Clinic is the lead sponsor of 3,263 studies on the registry; 670 are open to participants now.
Of its 450 completed or terminated interventional studies of FDA-regulated products, 318 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Self reported history of
Participants receive written and video self-collection instructions and complete vaginal HPV sample collection using self-collection brush with or without clinician assistance during screening appointment. Participants then receive testing results via phone call and mailed letter. Participants with abnormal test results also receive recommended next steps as well as communication to primary care team on study. Approximately 14-28 days after screening appointment, participants receive a phone call to verify receipt of results and/or outcomes of abnormal testing result follow-up.
Procedure: HPV Self-Collection · Other: Informational Intervention · Other: Interview · Other: Survey Administration · Procedure: Receive screening results · Procedure: Receive recommended steps following abnormal results · Behavioral: Telephone-Based Intervention
Complete self-collection of vaginal HPV sample alone or with clinician assistance
Also known as: Human Papillomavirus Self-Collection
Receive written and video self-collection instructions
Participants will be asked to take part in a brief interview to learn about their experience in the clinic and suggestions for improvement
Participants will be asked to take part in a brief survey to learn about their experience in the clinic and suggestions for improvement.
Receive testing results
Also known as: receive test results
Receive recommended next steps and primary care team communication
May receive verification phone call
Number of individuals screened in the community via this protocol
Assessed by the number of participants who undergo cervical cancer screening. Results will be analyzed descriptively.
Time frame: Up to 1 year
Number of abnormal screening results identified
Assessed by the number of participants who receive abnormal results such as positive HPV or invalid test result. Results will be analyzed descriptively.
Time frame: Up to 28 days
Follow up completed
Assessed by the number of participants with abnormal screening results who obtained follow-up testing as recommended. Results will be analyzed descriptively.
Time frame: Up to 3 months
Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.
Of 395 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 71. This study's planned 12 months is below that.
Counting every sponsor, half of 409 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.